Experienced in Medullary Thyroid Carcinoma

Dr. Kenneth D. Nahum

Hematology Oncology
Regional Cancer Care Associates, LLC
57 Kent Road, 
Howell, NJ 
Offers Telehealth
Experienced in Medullary Thyroid Carcinoma
Regional Cancer Care Associates, LLC
57 Kent Road, 
Howell, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kenneth Nahum is a Hematologist Oncology provider in Howell, New Jersey. Dr. Nahum is rated as an Experienced provider by MediFind in the treatment of Medullary Thyroid Carcinoma. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, Bone Marrow Aspiration, and Fasciotomy.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Robert Wood Johnson Medical School
Residency
Penn Presbyterian Medical Center
Specialties
Hematology Oncology
Licenses
Internal Medicine in NJ
Board Certifications
American Board Of Internal Medicine
Hematology
Fellowships
Robert Wood Johnson University Hospital
Hospital Affiliations
Community Medical Center
Ocean Medical Center
Centrastate Medical Center
Monmouth Medical Center-Southern Campus
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Regional Cancer Care Associates, LLC
57 Kent Road, Howell, NJ 7731.
Other Locations
HMH - John Theurer Cancer Center - Toms River
40 Bey Lea Road, Suite A202, Toms River, NJ 8753.
Jersey Shore University Medical Center
19 Davis Avenue, Suite A202, Neptune, NJ 7753.

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drugs: LEE011, Tamoxifen, Letrozole, Anastrozole, Goserelin
Study Phase: Phase 3
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Enrollment Status: Terminated
Publish Date: July 20, 2018
Intervention Type: Diagnostic test
View 3 Less Clinical Trials

5 Total Publications

An Interesting Case of Prostate Cancer Presenting With Colonic Metastasis.
An Interesting Case of Prostate Cancer Presenting With Colonic Metastasis.
Journal: Cureus
Published: February 03, 2023
Similar Doctors
Advanced in Medullary Thyroid Carcinoma
Dr. Megha Shah
Hematology Oncology | Hematology | Oncology
Advanced in Medullary Thyroid Carcinoma
Dr. Megha Shah
Hematology Oncology | Hematology | Oncology

Hunterdon Hematology Oncology, LLC

2100 Wescott Dr, 
Flemington, NJ 
 (43.1 miles away)
908-237-1201
Experience:
17+ years
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Megha Shah is a Hematologist Oncology specialist and a Hematologist in Flemington, New Jersey. Dr. Shah has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Medullary Thyroid Carcinoma. Her top areas of expertise are Familial Colorectal Cancer, Angiosarcoma, Paget Disease of the Breast, Breast Cancer, and Deep Brain Stimulation. Dr. Shah is currently accepting new patients.

Experienced in Medullary Thyroid Carcinoma
Dr. Christian M. Squillante
Hematology Oncology | Oncology | Hematology
Experienced in Medullary Thyroid Carcinoma
Dr. Christian M. Squillante
Hematology Oncology | Oncology | Hematology

Cmc Dept Of Medicine Group PA

900 Centennial Blvd M, 
Voorhees, NJ 
 (42.4 miles away)
856-325-6750
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Christian Squillante is a Hematologist Oncology specialist and an Oncologist in Voorhees, New Jersey. Dr. Squillante has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Medullary Thyroid Carcinoma. His top areas of expertise are Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer.

Experienced in Medullary Thyroid Carcinoma
Dr. James V. Fetten
Hematology Oncology | Oncology | Hematology
Experienced in Medullary Thyroid Carcinoma
Dr. James V. Fetten
Hematology Oncology | Oncology | Hematology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (45.5 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Fetten is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Fetten is rated as an Advanced provider by MediFind in the treatment of Medullary Thyroid Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Nasopharyngeal Carcinoma, Epithelial-Myoepithelial Carcinoma, and Merkel Cell Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nahum's expertise for a condition
ConditionClose
    View All 23 Distinguished Conditions
    View All 47 Advanced Conditions
    View All 156 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile